HealthQuill ATTR Amyloidosis
AstraZeneca Plc’s investigational drug to treat AL amyloidosis, a rare and serious disease affecting the heart and kidneys, failed to meet its main goal of helping people to live longer.
Drugs Health Pharma

AstraZeneca’s trial drug for AL amyloidosis fails to meet survival goal

HQ Team July 16, 2025: AstraZeneca Plc’s investigational drug to treat AL amyloidosis, a rare and serious disease affecting the heart and kidneys,.

Read More